Showing 51-60 of 6786 results for "".
RF Technologies: What should you know?
https://practicaldermatology.com/series/scientifically-speaking/rf-technologies-what-should-you-know/19848/With so many radiofrequency devices now on the market and new ones in development, aesthetic specialists need to know how to select the proper tool for each patient need. E. Victor Ross, MD and Erez Dayan, MD join host Joel L. Cohen, MD to go beyond the marketing jargon to assess the science and cliOn New Therapeutics and Real Sushi
https://practicaldermatology.com/series/the-practical-dermatology-podcast/on-new-therapeutics-and-real-sushi/32849/The latest news and updates, plus E. James Song, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the 2025 outlook for new therapeutics and play "Two Truths and a Lie." Dr. Song says he has been a wrestler, a jazz musician, and a sushi cheNext Generation Environmental Protection: Antioxidants and Chelators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/next-generation-environmental-protection-antioxidants-and-chelators/23802/As understanding of the pathogenesis of skin aging and carcinogenesis evolves, so do topical protective strategies.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eInbound Marketing: Why You Need a Strategy
https://practicaldermatology.com/topics/practice-management/inbound-marketing/18782/Focus on cultivating interactive marketing messages to show your audience what your practice is all about and what value it offers your target audience. "In your face" marketing is a thing of the past. Learn three strategies for successful inbound marketing for a medical practice in this Ekwa.com EThe Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and cJournal Club: A Comprehensive Update
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-a-comprehensive-update/32402/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses the recent Lancet article "Atopic Dermatitis" with primary author Emma Guttman, MD, PhD. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)0Questions on Established Patients, Medicare Services for Families, and Coding for Destructions
https://practicaldermatology.com/topics/practice-management/questions-on-established-patients-medicare-services-for-families-and-coding-for-destructions/21667/Seeing new patients doesn't necessarily provide better reimbursement than Established Patients. Here are answers to questions on this and other coding matters.Squamoid Eccrine Ductal Carcinoma: A Diagnostic Challenge
https://practicaldermatology.com/youngmd-connect/resident-resource-center/squamoid-eccrine-ductal-carcinoma-a-diagnostic-challenge/23970/Squamoid eccrine ductal carcinoma is often initially misdiagnosed as squamous cell carcinoma.Psoriasis: Exploring The Mind-Body Connection
https://practicaldermatology.com/topics/psoriasis/psoriasis-exploring-the-mind-body-connection/23428/Recognizing the complex relationship between stress and psoriasis is essential for comprehensive patient care.